Original Report: Patient-Oriented, Translational Research
Real-World Doxercalciferol Treatment in SHPT CKD Stage 3 and 4: An Analysis of Change in iPTH and Accordance to KDOQI RecommendationsKumar N.a · Lindberg J.b · David K.c · Morris J.c · Menoyo J.d
aNephrology and Hypertension, Kidney and Hypertension Center P.C. – Davita Dialysis Unit, Roseburg, Oreg., bNew Orleans Nephrology Associates, New Orleans, La., cProSanos Corp., Harrisburg, Pa., and dGenzyme Corp., Cambridge, Mass., USA
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: National Kidney Foundation’s Kidney Disease Outcome Quality Initiative (KDOQI) guidelines offer an outline for providing standardized care for best outcomes in chronic kidney disease (CKD). It is unknown whether real-world treatment practices follow these guidelines. Methods: The Hectorol® Registry Outcome in Chronic Kidney Disease (HeROICkd™), an observational patient registry, captured information on adult patients with CKD Stage 3 or 4 throughout US clinics during a 9-month observation period. Data were collected quarterly from patients’ medical records, throughout each patient’s normal treatment course. The proportion of patients with intact parathyroid hormone (iPTH) levels within KDOQI guidelines, change in iPTH, Ca, P, and Ca × P product over the 9-month observation period, incidence of hypercalcemia and hyperphosphatemia, and predictors of change in iPTH were examined. Results: 1,339 CKD Stage 3 and 4 patients from 78 nephrology and internal medicine clinics were included. 40% of CKD Stage 3 participants and 45% of Stage 4 had a 30% or greater reduction in iPTH levels from baseline to 9 months follow-up. While the proportion of CKD Stage 3 and 4 participants with iPTH levels within the KDOQI recommendations improved significantly over the 9 months, it was still modest, at 28% and 23%, respectively. Mean doxercalciferol dose was below that recommended in the package insert and a minority of patients had all mineral metabolism parameters (iPTH, Ca, P) regularly recorded in their medical records. Conclusions: The results of this registry, which examined iPTH treatment with doxercalciferol in CKD Stage 3 and 4, suggest that in the real-world treatment setting, the adherence to KDOQI guidelines is not optimal.
© 2008 S. Karger AG, Basel
- Craver L, Marco MP, Martínez I, Rue M, et al: Mineral metabolism parameters throughout chronic kidney disease stages 1–5 – achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007;22:1171–1176.
- Sherrard DJ, Hercz G, Pei Y, Maloney NA, et al: The spectrum of bone disease in end-stage renal failure: an evolving disorder. Kidney Int 1993;43:436–442.
- Salem MM: Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis 1997;29:862–865.
Andress DL: PTH in CKD Stages 3 and 4: The Need for Early Testing and Treatment. Improving Clinical Outcomes for Hemodialysis Patients in the International Dialysis Outcomes and Practice Pattern Studies (DOPPS). American Society of Nephrology Renal Week 2005, Philadelphia, November 8–13, 2005.
- Sherrard DJ, Hercz G, Pei Y, et al: The spectrum of bone disease in end-stage renal failure – an evolving disorder. Kidney Int 1993;43:436–442.
Fukagawa M, Kazama JJ, Kurokawa K: Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant 2002;17(suppl 10):2–5.
- Rostand SG, Drueke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999;56:383–392.
- Randon RB, Rohde LE, Comerlato L, Ribeiro JP, Manfro RC: The role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis. Braz J Med Biol Res 2005;38:1409–1416.
- Raggi P, Boulay A, Chasan-Taber SC, et al: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695–701.
Salgueira M, Del Toro N, Moreno-Alba R, Jimenez NA, Palma A: Vascular calcification in the uremic patient: a cardiovascular risk? Kidney Int 2003(suppl):S119–S121.
- Kestenbaum B, Belozeroff V: Mineral metabolism disturbances in patients with chronic kidney disease. Eur J Clin Invest 2007;37:607–622.
K/DOQI Clinical Practice Guidelines for Bone Metabolism, and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003;42:S1–S201.
- Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, et al: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858–1865.
- Young EW, Akiba T, Albert JM, McCarthy JT, et al: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:34–38.
- Dennis VC, Albertson GL: Doxercalciferol treatment of secondary hyperparathyroidism. Ann Pharmacother 2006;40:1955–1965.
Hectorol® – doxercalciferol capsules 2.5 μg. Genzyme, Cambridge/MA, USA.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.